Vanguard Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
Vanguard Asset Management's VRTX Position: Q2 2026 in Review
Vanguard Asset Management increased its Vertex Pharmaceuticals (VRTX) stake by 12% in Q2 2026, buying an estimated $23M and bringing the position to 494,186 shares worth $245M. The position accounts for 0.17% of the portfolio, ranked #104.
Vanguard Asset Management first reported a position in VRTX in Q1 2026 and has held it in 2 quarters since. 1,663 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Vanguard Asset Management held 494,186 shares of Vertex Pharmaceuticals worth $245M as of Q2 2026.
- Vanguard Asset Management bought 52,009 Vertex Pharmaceuticals shares in Q2 2026, an estimated $23M.
- Vertex Pharmaceuticals made up 0.17% of Vanguard Asset Management's portfolio in Q2 2026, its #104 holding.
- Vanguard Asset Management first reported a position in Vertex Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
- 1,663 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.